Molecular pathways underlying the pathogenesis of pancreatic α-cell dysfunction

Advances in Experimental Medicine and Biology

Volumn 654, Issue , 2010, Pages 421-445

  Kawamori, Dan ^b   Welters, Hannah J ^b   Kulkarni, Rohit N ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

cells; Counter regulation; Development; Diabetes; GABA; GLP 1; Glucagon; Hypertrophy; Hypoglycemia; Insulin; Neurotransmitters and nervous systems; Pancreatic islets; Secretion; Somatostatin; Zinc

Indexed keywords

4 AMINOBUTYRIC ACID; ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; GHRELIN; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCAGON RECEPTOR; GLUCOSE TRANSPORTER 2; HEPATOCYTE NUCLEAR FACTOR 3BETA; INSULIN; ION CHANNEL; LIRAGLUTIDE; NEUROGENIC DIFFERENTIATION FACTOR; OXYNTOMODULIN; PIOGLITAZONE; ROSIGLITAZONE; SOMATOSTATIN; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR MAFA; TRANSCRIPTION FACTOR MAFB; TRANSCRIPTION FACTOR NKX6.1; TRANSCRIPTION FACTOR PAX4; TRANSCRIPTION FACTOR PAX6; VILDAGLIPTIN; ZINC; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

AMINO ACID SEQUENCE; ARTICLE; CALCIUM CELL LEVEL; DEPOLARIZATION; DIABETES MELLITUS; DISEASE EXACERBATION; ELECTRIC ACTIVITY; ENZYME ACTIVATION; EXOCYTOSIS; GENE EXPRESSION; GLUCAGON RELEASE; GLUCAGONOMA; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; GLYCOLYSIS; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; NERVOUS SYSTEM; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL HYPERPLASIA; PANCREAS ISLET DISEASE; PANCREAS ISLET TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; HYPERGLYCEMIA; HYPERTROPHY; METABOLISM; PANCREAS; PANCREAS ISLET; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION; GLUCAGON; GLUCAGON-SECRETING CELLS; HUMANS; HYPERGLYCEMIA; HYPERTROPHY; ISLETS OF LANGERHANS; MODELS, BIOLOGICAL; NERVOUS SYSTEM; NEUROTRANSMITTER AGENTS; PANCREAS; SIGNAL TRANSDUCTION; SOMATOSTATIN;

EID: 77953939472     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-90-481-3271-3_18     Document Type: Article

References (174)

1. Cabrera O, Berman DM, Kenyon NS. et al. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A 2006;103:2334-9. (Pubitemid 43271670)
2. Bonner-Weir S, O'Brien TD. Islets in type 2 diabetes: in honor of Dr. Robert C. Turner. Diabetes 2008;57:2899-904.
3. Bonner-Weir S, Orci L. New perspectives on the microvasculature of the islets of Langerhans in the rat. Diabetes 1982;31:883-9. (Pubitemid 12013792)
4. Stagner JI, Samols E. Retrograde perfusion as a model for testing the relative effects of glucose versus insulin on the A cell. J Clin Invest 1986;77:1034-7. (Pubitemid 16067982)
5. Seino S, Welsh M, Bell GI. et al. Mutations in the guinea pig preproglucagon gene are restricted to a specific portion of the prohormone sequence. FEBS Lett 1986;203:25-30. (Pubitemid 16043485)
6. Exton JH, Jefferson LS, Jr., Butcher RW. et al. Gluconeogenesis in the perfused liver. The effects of fasting, alloxan diabetes, glucagon, epinephrine, adenosine 3', 5'-monophosphate and insulin. Am J Med 1966;40:709-15.
7. Unger RH, Orci L. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Annu Rev Med 1977;28:119-30.
8. Scheen AJ, Castillo MJ, Lefebvre PJ. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab 1996;22:397-406. (Pubitemid 26401312)
9. Prasadan K, Daume E, Preuett B. et al. Glucagon is required for early insulin-positive differentiation in the developing mouse pancreas. Diabetes 2002;51:3229-236. (Pubitemid 35246969)
10. Vuguin PM, Kedees MH, Cui L. et al. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology 2006;147:3995-4006. (Pubitemid 44268351)
11. Jelinek LJ, Lok S, Rosenberg GB. et al. Expression cloning and signaling properties of the rat glucagon receptor. Science 1993;259:1614-16. (Pubitemid 23114641)
12. Burcelin R, Li J, Charron MJ. Cloning and sequence analysis of the murine glucagon receptor-encoding gene. Gene 1995;164:305-10.
13. Weinstein LS, Yu S, Warner DR. et al. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 2001;22:675-705. (Pubitemid 32955250)
14. Wakelam MJ, Murphy GJ, Hruby VJ. et al. Activation of two signal-transduction systems in hepatocytes by glucagon. Nature 1986;323:68-71. (Pubitemid 16012350)
15. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003;284:E671-8. (Pubitemid 36323859)
16. Huypens P, Ling Z, Pipeleers D. et al. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 2000;43:1012-9. (Pubitemid 30655721)
17. Ma X, Zhang Y, Gromada J. et al. Glucagon stimulates exocytosis in mouse and rat pancreatic alpha-cells by binding to glucagon receptors. Mol Endocrinol 2005;19:198-212. (Pubitemid 40065970)
18. Holz GG, Kang G, Harbeck M. et al. Cell physiology of cAMP sensor Epac. J Physiol 2006;577:5-15. (Pubitemid 44698236)
19. Orci L, Baetens D, Rufener C. et al. Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes. Proc Natl Acad Sci U S A 1976;73:1338-42.
20. Dinneen S, Alzaid A, Turk D. et al. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 1995;38:337-43.
21. Larsson H, Ahren B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 2000;23:650-7. (Pubitemid 30321546)
22. Ahren B, Larsson H. Impaired glucose tolerance (IGT) is associated with reduced insulininduced suppression of glucagon concentrations. Diabetologia 2001;44:1998-2003. (Pubitemid 33124044)
23. Raskin P, Unger RH. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. N Engl J Med 1978;299:433-6. (Pubitemid 9011327)
24. Sherwin RS, Fisher M, Hendler R. et al. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. N Engl J Med 1976;294:455-61.
25. Mitrakou A, Kelley D, Mokan M. et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22-9.
26. Yoon KH, Ko SH, Cho JH. et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003;88:2300-8. (Pubitemid 36549911)
27. Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia 1983;24:366-71. (Pubitemid 13092224)
28. Meier JJ, Kjems LL, Veldhuis JD. et al. Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes 2006;55:1051-6. (Pubitemid 44100181)
29. Gerich JE, Langlois M, Noacco C. et al. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973;182:171-3.
30. Amiel SA, Sherwin RS, Simonson DC. et al. Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 1988;37:901-7. (Pubitemid 19043718)
31. Cryer PE. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994;43:1378-89.
32. Mokan M, Mitrakou A, Veneman T. et al. Hypoglycemia unawareness in IDDM. Diabetes Care 1994;17:1397-1403. (Pubitemid 24369723)
33. Powell AM, Sherwin RS, Shulman GI. Impaired hormonal responses to hypoglycemia in spontaneously diabetic and recurrently hypoglycemic rats. Reversibility and stimulus specificity of the deficits. J Clin Invest 1993;92:2667-74. (Pubitemid 24006531)
34. Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 1991;40:223-6.
35. Criego AB, Tkac I, Kumar A. et al. Brain glucose concentrations in patients with type 1 diabetes and hypoglycemia unawareness. J Neurosci Res 2005;79:42-7. (Pubitemid 40116416)
36. Zhou H, Tran PO, Yang S. et al. Regulation of alpha-cell function by the beta-cell during hypoglycemia in Wistar rats: the "switch-off " hypothesis. Diabetes 2004;53:1482-7. (Pubitemid 38697660)
37. Hope KM, Tran PO, Zhou H. et al. Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the "switch-off " hypothesis. Diabetes 2004;53:1488-95. (Pubitemid 38697661)
38. Zhou H, Zhang T, Oseid E. et al. Reversal of defective glucagon responses to hypoglycemia in insulin-dependent autoimmune diabetic BB rats. Endocrinology 2007;148:2863-9. (Pubitemid 46984800)
39. Pyzdrowski KL, Kendall DM, Halter JB. et al. Preserved insulin secretion and insulin independence in recipients of islet autografts. N Engl J Med 1992;327:220-6.
40. Shapiro AM, Lakey JR, Ryan EA. et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-8. (Pubitemid 30490390)
41. Ansara MF, Saudek F, Newton M. et al. Pancreatic islet transplantation prevents defective glucose counter-regulation in diabetic dogs. Transplant Proc 1994;26:664-5. (Pubitemid 24143656)
42. Kendall DM, Teuscher AU, Robertson RP. Defective glucagon secretion during sustained hypoglycemia following successful islet allo- and autotransplantation in humans. Diabetes 1997;46:23-7. (Pubitemid 27009944)
43. Gupta V, Wahoff DC, Rooney DP. et al. The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined. Diabetes 1997;46:28-33. (Pubitemid 27009945)
44. Zhou H, Zhang T, Bogdani M. et al. Intrahepatic glucose flux as a mechanism for defective intrahepatic islet alpha-cell response to hypoglycemia. Diabetes 2008;57:1567-74.
45. Mallinson CN, Bloom SR, Warin AP. et al. A glucagonoma syndrome. Lancet 1974;2:1-5.
46. McGavran MH, Unger RH, Recant L. et al. A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med 1966;274:1408-13.
47. Wilkinson DS. Necrolytic migratory erythema with pancreatic carcinoma. Proc R Soc Med 1971;64:1197-8.
48. Khandekar JD, Oyer D, Miller HJ. et al. Neurologic involvement in glucagonoma syndrome: response to combination chemotherapy with 5-fluorouracil and streptozotocin. Cancer 1979;44:2014-6. (Pubitemid 10210826)
49. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 1997;46:785-91. (Pubitemid 27188255)
50. Steiner DF. The proprotein convertases. Curr Opin Chem Biol 1998;2:31-9. (Pubitemid 128419196)
51. Rouille Y, Westermark G, Martin SK. et al. Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proc Natl Acad Sci U S A 1994;91:3242-6. (Pubitemid 24130212)
52. Furuta M, Zhou A, Webb G. et al. Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. J Biol Chem 2001;276:27197-202.
53. Scopsi L, Gullo M, Rilke F. et al. Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation. J Clin Endocrinol Metab 1995;80:294-301.
54. Gromada J, Franklin I, Wollheim CB. Alphα-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007;28:84-116. (Pubitemid 46220851)
55. Philippe J. Structure and pancreatic expression of the insulin and glucagon genes. Endocr Rev 1991;12:252-71.
56. Ritz-Laser B, Estreicher A, Klages N. et al. Pax-6 and Cdx-2/3 interact to activate glucagon gene expression on the G1 control element. J Biol Chem 1999;274:4124-32.
57. Petersen HV, Jorgensen MC, Andersen FG. et al. Pax4 represses pancreatic glucagon gene expression. Mol Cell Biol Res Commun 2000;3:249-54. (Pubitemid 30602032)
58. Ritz-Laser B, Estreicher A, Gauthier BR. et al. The pancreatic beta-cell-specific transcription factor Pax-4 inhibits glucagon gene expression through Pax-6. Diabetologia 2002; 45:97-107. (Pubitemid 34118547)
59. Katz LS, Gosmain Y, Marthinet E. et al. Pax6 regulates the proglucagon processing enzyme PC2 and its chaperone 7B2. Mol Cell Biol 2009.
60. Schinner S, Dellas C, Schroder M. et al. Repression of glucagon gene transcription by peroxisome proliferator-activated receptor gamma through inhibition of Pax6 transcriptional activity. J Biol Chem 2002;277:1941-8. (Pubitemid 34968772)
61. Kratzner R, Frohlich F, Lepler K. et al. A peroxisome proliferator-activated receptor gammaretinoid X receptor heterodimer physically interacts with the transcriptional activator PAX6 to inhibit glucagon gene transcription. Mol Pharmacol 2008;73:509-17. (Pubitemid 351159221)
62. Philippe J. Glucagon gene transcription is negatively regulated by insulin in a hamster islet cell line. J Clin Invest 1989;84:672-7.
63. Grzeskowiak R, Amin J, Oetjen E. et al. Insulin responsiveness of the glucagon gene conferred by interactions between proximal promoter and more distal enhancer-like elements involving the paired-domain transcription factor Pax6. J Biol Chem 2000;275:30037-45.
64. Schinner S, Barthel A, Dellas C. et al. Protein kinase B activity is sufficient to mimic the effect of insulin on glucagon gene transcription. J Biol Chem 2005;280:7369-76. (Pubitemid 40341295)
65. Gonzalez M, Boer U, Dickel C. et al. Loss of insulin-induced inhibition of glucagon gene transcription in hamster pancreatic islet alpha cells by long-term insulin exposure. Diabetologia 2008;51:2012-21.
66. Kawamori D, Kurpad AJ, Hu J. et al. Insulin signaling in alpha-cells modulates glucagon secretion in vivo. Cell Metab 2009;9:350-61.
67. MacDonald PE, De Marinis YZ, Ramracheya R. et al. A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol 2007;5:e143.
68. Gopel SO, Kanno T, Barg S. et al. Regulation of glucagon release in mouse-cells by KATP channels and inactivation of TTX-sensitive Na+ channels. J Physiol 2000;528:509-20.
69. Gromada J, Bokvist K, Ding WG. et al. Adrenaline stimulates glucagon secretion in pancreatic A-cells by increasing the Ca2+ current and the number of granules close to the L-type Ca2+ channels. J Gen Physiol 1997;110:217-28. (Pubitemid 27388115)
70. Olsen HL, Theander S, Bokvist K. et al. Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. Endocrinology 2005;146:4861-70. (Pubitemid 41446624)
71. Franklin I, Gromada J, Gjinovci A. et al. Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 2005;54:1808-15. (Pubitemid 40770771)
72. Quoix N, Cheng-Xue R, Mattart L. et al. Glucose and pharmacological modulators of ATPsensitive K+ channels control [Ca2+]c by different mechanisms in isolated mouse alphacells. Diabetes 2009;58:412-21.
73. Vieira E, Salehi A, Gylfe E. Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia 2007;50:370-9.
74. Ravier MA, Rutter GA. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. Diabetes 2005;54:1789-97. (Pubitemid 40770769)
75. Salehi A, Vieira E, Gylfe E. Paradoxical stimulation of glucagon secretion by high glucose concentrations. Diabetes 2006;55:2318-23. (Pubitemid 44743630)
76. Gerich JE, Lorenzi M, Schneider V. et al. Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics. Diabetes 1974;23:876-80.
77. Yamada H, Otsuka M, Hayashi M. et al. Ca2+-dependent exocytosis of L-glutamate by alphaTC6, clonal mouse pancreatic alpha-cells. Diabetes 2001;50:1012-20. (Pubitemid 32374531)
78. Cabrera O, Jacques-Silva MC, Speier S. et al. Glutamate is a positive autocrine signal for glucagon release. Cell Metab 2008;7:545-54. (Pubitemid 351729201)
79. Hayashi M, Otsuka M, Morimoto R. et al. Differentiation-associated Na+-dependent inorganic phosphate cotransporter (DNPI) is a vesicular glutamate transporter in endocrine glutamatergic systems. J Biol Chem 2001;276:43400-6.
80. Bloom SR, Edwards AV, Hardy RN. The role of the autonomic nervous system in the control of glucagon, insulin and pancreatic polypeptide release from the pancreas. J Physiol 1978;280:9-23. (Pubitemid 8398555)
81. Ahren B. Autonomic regulation of islet hormone secretion - implications for health and disease. Diabetologia 2000;43:393-410. (Pubitemid 30237947)
82. Evans ML, McCrimmon RJ, Flanagan DE. et al. Hypothalamic ATP-sensitive K + channels play a key role in sensing hypoglycemia and triggering counterregulatory epinephrine and glucagon responses. Diabetes 2004;53:2542-51. (Pubitemid 39299260)
83. Marty N, Dallaporta M, Foretz M. et al. Regulation of glucagon secretion by glucose transporter type 2 (glut2) and astrocyte-dependent glucose sensors. J Clin Invest 2005;115:3545-53. (Pubitemid 43121842)
84. Schuit FC, Pipeleers DG. Differences in adrenergic recognition by pancreatic A and B cells. Science 1986;232:875-7. (Pubitemid 16117398)
85. Vieira E, Liu YJ, Gylfe E. Involvement of alpha1 and beta-adrenoceptors in adrenaline stimulation of the glucagon-secreting mouse alpha-cell. Naunyn Schmiedebergs Arch Pharmacol 2004;369:179-83. (Pubitemid 38270773)
86. Borg WP, Sherwin RS, During MJ. et al. Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release. Diabetes 1995;44:180-4.
87. McCrimmon RJ, Fan X, Ding Y. et al. Potential role for AMP-activated protein kinase in hypoglycemia sensing in the ventromedial hypothalamus. Diabetes 2004;53:1953-8. (Pubitemid 38970741)
88. Cheng H, Zhou L, Zhu W. et al. Type 1 corticotropin-releasing factor receptors in the ventromedial hypothalamus promote hypoglycemia-induced hormonal counterregulation. Am J Physiol Endocrinol Metab 2007;293:E705-12. (Pubitemid 47358982)
89. Samols E, Stagner JI. Intra-islet regulation. Am J Med 1988;85:31-5. (Pubitemid 19012371)
90. Weir GC, Knowlton SD, Atkins RF. et al. Glucagon secretion from the perfused pancreas of streptozotocin-treated rats. Diabetes 1976;25:275-82.
91. Asplin CM, Paquette TL, Palmer JP. In vivo inhibition of glucagon secretion by paracrine beta cell activity in man. J Clin Invest 1981;68:314-8. (Pubitemid 11048106)
92. Maruyama H, Hisatomi A, Orci L. et al. Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 1984;74:2296-9. (Pubitemid 15197376)
93. Bhathena SJ, Oie HK, Gazdar AF. et al. Insulin, glucagon, and somatostatin receptors on cultured cells and clones from rat islet cell tumor. Diabetes 1982;31:521-31. (Pubitemid 12119339)
94. Patel YC, AmherdtM, Orci L. Quantitative electron microscopic autoradiography of insulin, glucagon, and somatostatin binding sites on islets. Science 1982;217:1155-6. (Pubitemid 12069037)
95. Greenbaum CJ, Havel PJ, Taborsky GJ, Jr. et al. Intra-islet insulin permits glucose to directly suppress pancreatic A cell function. J Clin Invest 1991;88:767-73.
96. Gerich JE, Tsalikian E, Lorenzi M. et al. Normalization of fasting hyperglucagonemia and excessive glucagon responses to intravenous arginine in human diabetes mellitus by prolonged infusion of insulin. J Clin Endocrinol Metab 1975;41:1178-80.
97. Raju B, Cryer PE. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. Diabetes 2005;54:757-64. (Pubitemid 40322079)
98. Banarer S, McGregor VP, Cryer PE. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 2002;51:958-65. (Pubitemid 34438337)
99. Diao J, Asghar Z, Chan CB. et al. Glucose-regulated glucagon secretion requires insulin receptor expression in pancreatic alpha-cells. J Biol Chem 2005;280:33487-96. (Pubitemid 41397148)
100. Leung YM, Ahmed I, Sheu L. et al. Insulin regulates islet alpha-cell function by reducing KATP channel sensitivity to adenosine 5'-triphosphate inhibition. Endocrinology 2006;147:2155-62.
101. Xu E, Kumar M, Zhang Y. et al. Intra-islet insulin suppresses glucagon release via GABAGABAA receptor system. Cell Metab 2006;3:47-58.
102. Meier JJ, Nauck MA, Pott A. et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006;130:44-54. (Pubitemid 43049834)
103. Kittler JT, Moss SJ. Modulation of GABAA receptor activity by phosphorylation and receptor trafficking: implications for the efficacy of synaptic inhibition. Curr Opin Neurobiol 2003;13:341-7. (Pubitemid 36792247)
104. Sorenson RL, Garry DG, Brelje TC. Structural and functional considerations of GABA in islets of Langerhans. Beta-cells and nerves. Diabetes 1991;40:1365-74.
105. Rorsman P, Berggren PO, Bokvist K. et al. Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels. Nature 1989;341:233-6. (Pubitemid 19231723)
106. Wendt A, Birnir B, Buschard K. et al. Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells. Diabetes 2004;53:1038-45. (Pubitemid 38436616)
107. Ishihara H, Maechler P, Gjinovci A. et al. Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nat Cell Biol 2003;5:330-5. (Pubitemid 36432297)
108. Gyulkhandanyan AV, Lu H, Lee SC. et al. Investigation of transport mechanisms and regulation of intracellular Zn2+ in pancreatic alpha-cells. J Biol Chem 2008;283:10184-97.
109. Starke A, Imamura T, Unger RH. Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration. J Clin Invest 1987;79:20-4. (Pubitemid 17232493)
110. Barden N, Lavoie M, Dupont A. et al. Stimulation of glucagon release by addition of antisomatostatin serum to islets of Langerhans in vitro. Endocrinology 1977;101:635-8. (Pubitemid 8160931)
111. Yoshimoto Y, Fukuyama Y, Horio Y. et al. Somatostatin induces hyperpolarization in pancreatic islet alpha cells by activating a G protein-gated K+ channel. FEBS Lett 1999;444:265-9. (Pubitemid 29092815)
112. Schuit FC, Derde MP, Pipeleers DG. Sensitivity of rat pancreatic A and B cells to somatostatin. Diabetologia 1989;32:207-12. (Pubitemid 19117103)
113. Gromada J, Hoy M, Buschard K. et al. Somatostatin inhibits exocytosis in rat pancreatic alpha-cells by G(i2)-dependent activation of calcineurin and depriming of secretory granules. J Physiol 2001;535:519-32. (Pubitemid 32825687)
114. Gerber PP, Trimble ER, Wollheim CB. et al. Glucose and cyclic AMP as stimulators of somatostatin and insulin secretion from the isolated, perfused rat pancreas: a quantitative study. Diabetes 1981;30:40-4. (Pubitemid 11022622)
115. Honey RN, Schwarz JA, Mathe CJ. et al. Insulin, glucagon, and somatostatin secretion from isolated perfused rat and chicken pancreas-duodenum. Am J Physiol 1980;238:E150-6.
116. Hauge-Evans AC, King AJ, Carmignac D. et al. Somatostatin secreted by islet deltα-cells fulfils multiple roles as a paracrine regulator of islet function. Diabetes 2009;58:403-11.
117. Gerich JE. Role of somatostatin and its analogues in the pathogenesis and treatment of diabetes mellitus. Metabolism 1990;39:52-4. (Pubitemid 20286335)
118. Estall JL, Drucker DJ. Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 2006;12:1731-50.
119. Collombat P, Hecksher-Sorensen J, Broccoli V. et al. The simultaneous loss of Arx and Pax4 genes promotes a somatostatin-producing cell fate specification at the expense of the alphaand beta-cell lineages in the mouse endocrine pancreas. Development 2005;132:2969-80. (Pubitemid 41086732)
120. Li Y, Cao X, Li LX. et al. Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005; 54:482-91.
121. de Heer J, Rasmussen C, Coy DH. et al. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008;51:2263-70.
122. Creutzfeldt WO, Kleine N, Willms B. et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996;19:580-6.
123. Silvestre RA, Rodriguez-Gallardo J, Egido EM. et al. Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur J Pharmacol 2003;469:195-200. (Pubitemid 36629566)
124. Moens K, Heimberg H, Flamez D. et al. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 1996;45:257-61. (Pubitemid 26048675)
125. Tornehave D, Kristensen P, Romer J. et al. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 2008;56:841-51.
126. Meier JJ, Gallwitz B, Siepmann N. et al. Gastric inhibitory polypeptide (GIP) dosedependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003;46:798-801. (Pubitemid 36831408)
127. Pederson RA, Brown JC. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology 1978;103:610-5. (Pubitemid 8393743)
128. de Heer J, Pedersen J, Orskov C. et al. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 2007;50:2135-42. (Pubitemid 47373847)
129. Stagner JI, Samols E, Marks V. The anterograde and retrograde infusion of glucagon antibodies suggests that A cells are vascularly perfused before D cells within the rat islet. Diabetologia 1989;32:203-6. (Pubitemid 19117102)
130. Jorgensen MC, Ahnfelt-Ronne J, Hald J. et al. An illustrated review of early pancreas development in the mouse. Endocr Rev 2007;28:685-705. (Pubitemid 47606652)
131. Herrera PL, Huarte J, Sanvito F. et al. Embryogenesis of the murine endocrine pancreas; early expression of pancreatic polypeptide gene. Development 1991;113:1257-65.
132. Teitelman G, Alpert S, Polak JM. et al. Precursor cells of mouse endocrine pancreas coexpress insulin, glucagon and the neuronal proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic polypeptide. Development 1993;118:1031-9. (Pubitemid 23252394)
133. Jonsson J, Carlsson L, Edlund T. et al. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 1994;371:606-9. (Pubitemid 24315741)
134. Ahlgren U, Pfaff SL, Jessell TM. et al. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature 1997;385:257-60. (Pubitemid 27043725)
135. Gradwohl G, Dierich A, LeMeur M. et al. neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. Proc Natl Acad Sci U S A 2000;97:1607-11. (Pubitemid 30118489)
136. St-Onge L, Sosa-Pineda B, Chowdhury K. et al. Pax6 is required for differentiation of glucagon-producing alpha-cells in mouse pancreas. Nature 1997;387:406-9. (Pubitemid 27227205)
137. Heller RS, Stoffers DA, Liu A. et al. The role of Brn4/Pou3f4 and Pax6 in forming the pancreatic glucagon cell identity. Dev Biol 2004;268:123-34. (Pubitemid 38367855)
138. DoyleMJ, Loomis ZL, Sussel L. Nkx2.2-repressor activity is sufficient to specify alpha-cells and a small number of beta-cells in the pancreatic islet. Development 2007;134:515-23. (Pubitemid 46332488)
139. Collombat P, Mansouri A, Hecksher-Sorensen J. et al. Opposing actions of Arx and Pax4 in endocrine pancreas development. Genes Dev 2003;17:2591-603. (Pubitemid 37271428)
140. Collombat P, Hecksher-Sorensen J, Krull J. et al. Embryonic endocrine pancreas and mature beta cells acquire alpha and PP cell phenotypes upon Arx misexpression. J Clin Invest 2007;117:961-70. (Pubitemid 46556752)
141. Artner I, Le Lay J, Hang Y. et al. MafB: an activator of the glucagon gene expressed in developing islet alpha- and beta-cells. Diabetes 2006;55:297-304. (Pubitemid 43343256)
142. Nishimura W, Kondo T, Salameh T. et al. A switch from MafB to MafA expression accompanies differentiation to pancreatic beta-cells. Dev Biol 2006;293:526-39.
143. Nishimura W, Rowan S, Salameh T. et al. Preferential reduction of beta cells derived from Pax6-MafB pathway in MafB deficient mice. Dev Biol 2008;314:443-56.
144. Lee CS, Sund NJ, Behr R. et al. Foxa2 is required for the differentiation of pancreatic alphacells. Dev Biol 2005;278:484-95. (Pubitemid 40175044)
145. Lyttle BM, Li J, Krishnamurthy M. et al. Transcription factor expression in the developing human fetal endocrine pancreas. Diabetologia 2008;51:1169-80.
146. Deng S, Vatamaniuk M, Huang X. et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004;53:624-32. (Pubitemid 38270631)
147. Morley MG, Leiter EH, Eisenstein AB. et al. Dietary modulation of alpha-cell volume and function in strain 129/J mice. Am J Physiol 1982;242:G354-9. (Pubitemid 12097133)
148. Ellingsgaard H, Ehses JA, Hammar EB. et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 2008;105:13163-8.
149. Sloop KW, Cao JX, Siesky AM. et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004;113:1571-81. (Pubitemid 39071680)
150. Chen M, Gavrilova O, Zhao WQ. et al. Increased glucose tolerance and reduced adiposity in the absence of fasting hypoglycemia in mice with liver-specific Gs alpha deficiency. J Clin Invest 2005;115:3217-27. (Pubitemid 41567586)
151. Liang Y, Osborne MC, Monia BP. et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 2004;53:410-7. (Pubitemid 38174557)
152. Vincent M, Guz Y, Rozenberg M. et al. Abrogation of protein convertase 2 activity results in delayed islet cell differentiation and maturation, increased alpha-cell proliferation, and islet neogenesis. Endocrinology 2003;144:4061-9. (Pubitemid 37088761)
153. Webb GC, Akbar MS, Zhao C. et al. Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes 2002;51:398-405. (Pubitemid 34764795)
154. Cantley J, Choudhury AI, Asare-Anane H. et al. Pancreatic deletion of insulin receptor substrate 2 reduces beta and alpha cell mass and impairs glucose homeostasis in mice. Diabetologia 2007;50:1248-56. (Pubitemid 46701548)
155. Poy MN, Hausser J, Trajkovski M. et al. miR-375 maintains normal pancreatic {alpha}- and {beta}-cell mass. Proc Natl Acad Sci USA 2009;106:5813-18.
156. Johnson DG, Goebel CU, Hruby VJ. et al. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 1982;215:1115-6. (Pubitemid 12114094)
157. Madsen P, Brand CL, Holst JJ. et al. Advances in non-peptide glucagon receptor antagonists. Curr Pharm Des 1999;5:683-91. (Pubitemid 29510791)
158. Ling A, Hong Y, Gonzalez J. et al. Identification of alkylidene hydrazides as glucagon receptor antagonists. J Med Chem 2001;44:3141-9. (Pubitemid 32862345)
159. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001;44:2018-24. (Pubitemid 33124047)
160. Kodra JT, Jorgensen AS, Andersen B. et al. Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor. J Med Chem 2008;51:5387-96.
161. Brand CL, Rolin B, Jorgensen PN. et al. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocindiabetic rats. Diabetologia 1994;37:985-93. (Pubitemid 24300455)
162. Brand CL, Jorgensen PN, Svendsen I. et al. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 1996;45:1076-83. (Pubitemid 26260161)
163. Sorensen H, Brand CL, Neschen S. et al. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 2006;55:2843-48. (Pubitemid 44923685)
164. Yildirim S, Bolkent S, Sundler F. The role of rosiglitazone treatment in the modulation of islet hormones and hormone-like peptides: a combined in situ hybridization and immunohistochemical study. J Mol Histol 2008;39:635-42.
165. Ravikumar B, Gerrard J, Dalla Man C. et al. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes 2008;57:2288-95.
166. Gastaldelli A, Casolaro A, Pettiti M. et al. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. Clin Pharmacol Ther 2007;81:205-12. (Pubitemid 46174817)
167. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88. (Pubitemid 38045329)
168. Barnett AH. Exenatide. Drugs Today (Barc) 2005;41:563-78. (Pubitemid 41810472)
169. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 2009;297:137-40.
170. Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2008;68:2387-409.
171. Mentlein R, Gallwitz B, SchmidtWE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35. (Pubitemid 23188160)
172. Balas B, Baig MR, Watson C. et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92:1249-55. (Pubitemid 46556394)
173. Longuet C, Sinclair EM, Maida A. et al. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab 2008;8:359-71.
174. Sinclair EM, Yusta B, Streutker C. et al. Glucagon receptor signaling is essential for control of murine hepatocyte survival. Gastroenterology 2008;135:2096-106.